Onco-Innovations has strengthened its scientific leadership with the appointment of Dr. Dennis Hall, a globally respected figure in organoboron chemistry and medicinal innovation, to its Scientific and Clinical Advisory Board. Dr. Hall, currently a Tier 1 Canada Research Chair at the University of Alberta, brings a wealth of experience in drug discovery, catalysis, and chemical biology. His academic portfolio includes more than 175 peer-reviewed publications and recognition from major scientific societies, including the American Chemical Society and the Royal Society of Canada. His appointment reflects Onco-Innovations' commitment to infusing deep scientific expertise into its translational research efforts.

The decision to bring Dr. Hall on board is strategically aligned with the company’s ambitions to accelerate development of its lead platform, the Polynucleotide Kinase 3 Phosphatase (PNKP) Inhibitor Technology NP/A83. Dr. Hall’s groundbreaking research in boron-containing compounds offers direct relevance to the synthesis and optimization of targeted cancer therapies. His expertise will play a critical role in guiding Onco’s preclinical and clinical strategies, ensuring the integrity and innovation of its drug design and manufacturing processes, while fostering a multidisciplinary approach to solving complex oncological challenges.

Looking ahead, Dr. Hall’s collaboration with the company’s internal teams and external partners is expected to enhance Onco-Innovations’ R&D capabilities and streamline its path to clinical translation. His insights will help refine drug candidate selection, improve synthetic efficiency, and bolster scientific credibility with regulatory and investor stakeholders. As Onco-Innovations progresses toward clinical trials for its PNKP inhibitor program, Dr. Hall’s leadership will be instrumental in driving the company’s vision of delivering next-generation precision therapies for patients with difficult-to-treat cancers.